UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination

Vaccine, 2009-11, Vol.27 (47), p.6550-6557

2009

Volltextzugriff (PDF)

Evaluation of the Impact of Hepatitis B Vaccination among Children Born during 1992–2005 in China

The Journal of infectious diseases, 2009-07, Vol.200 (1), p.39-47

2009

Volltextzugriff (PDF)

A mathematical model to estimate global hepatitis B disease burden and vaccination impact

International journal of epidemiology, 2005-12, Vol.34 (6), p.1329-1339

2005

Volltextzugriff (PDF)

A Population-Based Acute Meningitis and Encephalitis Syndromes Surveillance in Guangxi, China, May 2007-June 2012

PloS one, 2015-12, Vol.10 (12), p.e0144366-e0144366

2015

Volltextzugriff (PDF)

Population-based surveillance for bacterial meningitis in China, September 2006-December 2009

Emerging infectious diseases, 2014-01, Vol.20 (1), p.61-69

2014

Volltextzugriff (PDF)

Supporting National Immunization Technical Advisory Groups (NITAGs) in development of evidence-based vaccine recommendations and NITAG assessments – New tools and approaches

Vaccine, 2024-10, Vol.42, p.125610, Article 125610

2024

Volltextzugriff (PDF)

Region-wide assessment of National Immunization Technical Advisory Groups (NITAGs) using the NITAG Maturity Assessment Tool (NMAT) – Experience from the Eastern Mediterranean Region of the World Health Organization, 2023

Vaccine, 2024-04, Vol.42 (9), p.2239-2245

2024

Volltextzugriff (PDF)

Hepatitis A surveillance and vaccine use in China from 1990 through 2007

Journal of epidemiology, 2009, Vol.19 (4), p.189-195

2009

Volltextzugriff (PDF)

Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination

Vaccine, 2013-12, Vol.31, p.J21-J28

2013

Volltextzugriff (PDF)

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021

MMWR. Morbidity and mortality weekly report, 2021-07, Vol.70 (27), p.977-982

2021

Volltextzugriff (PDF)

Respiratory Illness Caused by Corynebacterium diphtheriae and C. ulcerans, and Use of Diphtheria Antitoxin in the United States, 1996–2018

Clinical infectious diseases, 2021-11, Vol.73 (9), p.e2799-e2806

2021

Volltextzugriff (PDF)

The Brighton collaboration standardized module for vaccine benefit-risk assessment

Vaccine, 2024-02, Vol.42 (4), p.972-986

2024

Volltextzugriff (PDF)

A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States

Vaccine, 2023-10, Vol.41 (44), p.6456-6467

2023

Volltextzugriff (PDF)

Pertussis control: time for something new?

Trends in microbiology (Regular ed.), 2012-05, Vol.20 (5), p.211-213

2012

Volltextzugriff (PDF)

Ancillary benefits of seasonal influenza vaccination in middle-income countries

Vaccine, 2021-04, Vol.39 (14), p.1892-1896

2021

Volltextzugriff (PDF)

The impact of hepatitis B vaccine in China and in the China GAVI Project

Vaccine, 2013-12, Vol.31, p.J66-J72

2013

Volltextzugriff (PDF)

Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations

Risk analysis, 2018-08, Vol.38 (8), p.1701-1717

2018

Volltextzugriff (PDF)

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021

MMWR. Morbidity and mortality weekly report, 2021-04, Vol.70 (17), p.651-656

2021

Volltextzugriff (PDF)

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021

MMWR. Morbidity and mortality weekly report, 2021-08, Vol.70 (32), p.1094-1099

2021

Volltextzugriff (PDF)

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021

MMWR. Morbidity and mortality weekly report, 2021-11, Vol.70 (45), p.1579-1583

2021

Volltextzugriff (PDF)

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021

MMWR. Morbidity and mortality weekly report, 2021-03, Vol.70 (9), p.329-332

2021

Volltextzugriff (PDF)

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021

MMWR. Morbidity and mortality weekly report, 2021-11, Vol.70 (44), p.1545-1552

2021

Volltextzugriff (PDF)

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021

MMWR. Morbidity and mortality weekly report, 2021-05, Vol.70 (20), p.749-752

2021

Volltextzugriff (PDF)

Preventing hepatitis B though universal vaccination: Reduction of inequalities through the GAVI China project

Vaccine, 2013-12, Vol.31, p.J29-J35

2013

Volltextzugriff (PDF)

Country Data for Action: The MenAfriNet Experience in Strengthening Meningitis Surveillance in Africa

The Journal of infectious diseases, 2019-10, Vol.220 (220 Suppl 4), p.S137-S139

2019

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(133)

Publikationsform

Sprache

Englisch
(188)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination

Evaluation of the Impact of Hepatitis B Vaccination among Children Born during 1992–2005 in China

A mathematical model to estimate global hepatitis B disease burden and vaccination impact

A Population-Based Acute Meningitis and Encephalitis Syndromes Surveillance in Guangxi, China, May 2007-June 2012

Population-based surveillance for bacterial meningitis in China, September 2006-December 2009

Supporting National Immunization Technical Advisory Groups (NITAGs) in development of evidence-based vaccine recommendations and NITAG assessments – New tools and approaches

Region-wide assessment of National Immunization Technical Advisory Groups (NITAGs) using the NITAG Maturity Assessment Tool (NMAT) – Experience from the Eastern Mediterranean Region of the World Health Organization, 2023

Hepatitis A surveillance and vaccine use in China from 1990 through 2007

Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021

Respiratory Illness Caused by Corynebacterium diphtheriae and C. ulcerans, and Use of Diphtheria Antitoxin in the United States, 1996–2018

The Brighton collaboration standardized module for vaccine benefit-risk assessment

A summary of the Advisory Committee for Immunization Practices (ACIP) use of a benefit-risk assessment framework during the first year of COVID-19 vaccine administration in the United States

Pertussis control: time for something new?

Ancillary benefits of seasonal influenza vaccination in middle-income countries

The impact of hepatitis B vaccine in China and in the China GAVI Project

Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021

Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021

The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021

Preventing hepatitis B though universal vaccination: Reduction of inequalities through the GAVI China project

Country Data for Action: The MenAfriNet Experience in Strengthening Meningitis Surveillance in Africa

Suchergebnisse filtern